Source: StemCells, Inc.
Date: February 17, 2011
Summary:
StemCells, Inc. today announced that the fourth and final patient in its Phase I clinical trial in Pelizaeus-Merzbacher Disease (PMD) has been transplanted with the Company's HuCNS-SC(R) cells (purified human neural stem cells). PMD is a fatal myelination disorder that afflicts male children. This clinical trial, which is being conducted in collaboration with UCSF Benioff Children's Hospital, is the first to evaluate neural stem cells as a potential treatment for a myelination disorder. Results of the trial will be reported in early 2012.
